51480 Efficacy of apremilast in adults with mild-to-moderate plaque psoriasis with scalp involvement: Pooled data from PROMINENT, ADVANCE, and EMBRACE trials
Recommended Citation
Stein-Gold L, Augustin M, Sofen H, Gisondi P, Jardon S, Reddy J, Zou H, Callis Duffin K. 51480 Efficacy of apremilast in adults with mild-to-moderate plaque psoriasis with scalp involvement: Pooled data from PROMINENT, ADVANCE, and EMBRACE trials. J Am Acad Dermatol 2024; 91(3):AB198.
Document Type
Conference Proceeding
Publication Date
9-1-2024
Publication Title
J Am Acad Dermatol
Abstract
Background: Plaque psoriasis (PsO) with scalp involvement occurs in 65-80% of PsO (1,2), yet most patients are dissatisfied with scalp topical therapies (3,4). Apremilast, an oral immunomodulating phosphodiesterase-4 inhibitor approved for PsO, has demonstrated efficacy in a placebo-controlled RCT involving moderate-to-severe PsO with scalp involvement (5). In patients with limited skin involvement, scalp involvement exacerbates PsO burden. Here, findings from a pooled analysis of apremilast efficacy data are presented. Methods: Data from PROMINENT (6), ADVANCE (7) and EMBRACE (8) patients with baseline body surface area (BSA) <10%, baseline Scalp Physician Global Assessment (ScPGA) ≥2, and ≥1 post-baseline ScPGA value were pooled. Outcomes were achievement of ScPGA response (clear/almost clear [0/1]), static Physician Global Assessment (sPGA) score cleared/minimal (0/1) with ≥2-grade improvement (sPGA response), ≥75% BSA improvement (BSA-75), Psoriasis Area and Severity Index score <3 (PASI<3), and ≥4-point reduction in the patient-reported outcome (PRO) of Dermatology Life Quality Index (DLQI) score at 16 weeks. Results: Pooled data from 548 patients (apremilast: 336; placebo: 212) showed mean baseline ScPGA and sPGA of 2.7 and 2.6, respectively, in each treatment group. A significantly higher proportion of patients achieved ScPGA response with apremilast than placebo (46.7% vs 19.8%; P<0.0001) at 16 weeks. sPGA, BSA-75, and PASI<3 skin responses significantly improved with apremilast vs placebo (23.8% vs 6.9%; 26.8% vs 7.1%; 53.9% vs 18.9%, respectively, P<0.0001). DLQI score significantly improved with apremilast vs placebo (61.1% vs 31.2%; P<0.0001). Conclusions: Apremilast demonstrated consistent significant efficacy and PRO improvement in PsO patients with scalp and limited skin involvement at 16 weeks.
Volume
91
Issue
3
First Page
AB198
